Biopharma has never generated more data, more innovation or more scientific exchange.
Yet despite being one of the most valuable assets for improving patient outcomes, medical insights from the field remain underused.
The industry is facing a structural paradox. Breakthrough therapies are becoming more complex and targeted, but bringing them to market is slower, more expensive and more uncertain. Up to 90% of medicines that enter clinical development never reach the market.
Check out the rest of the feature here
